328 related articles for article (PubMed ID: 16644315)
1. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Atar S; Cannon CP; Murphy SA; Rosanio S; Uretsky BF; Birnbaum Y
Am Heart J; 2006 May; 151(5):976.e1-6. PubMed ID: 16644315
[TBL] [Abstract][Full Text] [Related]
2. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G; Cannon CP; McCabe CH; Michowitz Y; Kaluski E; Charlesworth A; Milo O; Bentley J; Blatt A; Krakover R; Zimlichman R; Reisin L; Marmor A; Lewis B; Vered Z; Caspi A; Braunwald E;
Am Heart J; 2003 Apr; 145(4):622-7. PubMed ID: 12679757
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Smith EE; Cannon CP; Murphy S; Feske SK; Schwamm LH
Am Heart J; 2006 Feb; 151(2):338-44. PubMed ID: 16442896
[TBL] [Abstract][Full Text] [Related]
4. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
5. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Cannon CP; McCabe CH; Wilcox RG; Langer A; Caspi A; Berink P; Lopez-Sendon J; Toman J; Charlesworth A; Anders RJ; Alexander JC; Skene A; Braunwald E
Circulation; 2000 Jul; 102(2):149-56. PubMed ID: 10889124
[TBL] [Abstract][Full Text] [Related]
6. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
7. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Cantor WJ; Goodman SG; Cannon CP; Murphy SA; Charlesworth A; Braunwauld E; Langer A
Am Heart J; 2005 Feb; 149(2):275-83. PubMed ID: 15846265
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
O'Connor FF; Shields DC; Fitzgerald A; Cannon CP; Braunwald E; Fitzgerald DJ
Blood; 2001 Dec; 98(12):3256-60. PubMed ID: 11719362
[TBL] [Abstract][Full Text] [Related]
9. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
Chang SM; Yazbek N; Lakkis NM
Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
Schreiner GC; Laine L; Murphy SA; Cannon CP
Crit Pathw Cardiol; 2007 Dec; 6(4):169-72. PubMed ID: 18091407
[TBL] [Abstract][Full Text] [Related]
11. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Shields DC; Fitzgerald AP; O'Neill PA; Muckian C; Kenny D; Moran B; Cannon CP; Byrne CE; Fitzgerald DJ
Pharmacogenomics J; 2002; 2(3):182-90. PubMed ID: 12082590
[TBL] [Abstract][Full Text] [Related]
12. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial.
Smith CS; Cannon CP; McCabe CH; Murphy SA; Bentley J; Braunwald E
Am Heart J; 2005 Mar; 149(3):444-50. PubMed ID: 15864232
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Scirica BM; Cannon CP; Cooper R; Aster RH; Brassard J; McCabe CH; Charlesworth A; Skene AM; Braunwald E
J Thromb Thrombolysis; 2006 Oct; 22(2):95-102. PubMed ID: 17008974
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
18. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
[TBL] [Abstract][Full Text] [Related]
19. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
Collard CD; Body SC; Shernan SK; Wang S; Mangano DT; ;
J Thorac Cardiovasc Surg; 2006 Aug; 132(2):392-400. PubMed ID: 16872968
[TBL] [Abstract][Full Text] [Related]
20. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
